DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a revenue decline due to a legacy client nonrenewal, the company shows strong operational efficiency with reduced expenses and improved margins. Strategic partnerships with major health plans and a growing pipeline indicate future growth potential. The Q&A session highlighted confidence in meeting analyst expectations and achieving cash flow positivity. The company's proactive cost management and strategic partnerships are positive indicators, despite economic uncertainties and competitive pressures. Overall, these factors suggest a positive sentiment towards stock performance in the short term.
Key Financial Performance
Annual Revenue $22.4 million in 2025 compared to $27 million in 2024, a decline due to a single legacy client nonrenewal from the 2 acquisition, partially offset by organic growth.
Fourth Quarter Revenue $5.2 million in Q4 2025, showing sequential revenue growth.
GAAP Gross Margin Expanded from 49% in 2024 to 57% in 2025, primarily reflecting the reduction in technology amortization expenses.
Core B2B2C ARR Business Gross Margin Approximately 80% non-GAAP gross margin sustained for 2 years, representing the underlying unit economics of the platform.
Full Year Operating Expenses Declined by 31% to $49.3 million in 2025 compared to 2024. Non-GAAP operating expenses declined by 26% year-over-year from $52.2 million to $38.6 million.
Fourth Quarter Operating Expenses GAAP operating expenses declined 28% to $11.4 million in Q4 2025. Non-GAAP operating expenses also fell 28% year-over-year from $12.4 million to $9 million.
Full Year Operating Loss Improved by $21 million or 37% on a GAAP basis and by $9.6 million or 29% on a non-GAAP basis.
Net Cash Used in Operating Activities Declined from $38.6 million in 2024 to $25.9 million in 2025, a 33% reduction driven by margin expansion, AI utilization, and cost discipline.
Cash and Short-Term Deposits $26 million at the end of 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DarioIQ AI-driven intelligence engine: Trained on over 13 billion real-world data points, leveraging proprietary clinical data, and offering measurable outcomes for diabetes, hypertension, and mental health.
New agreements and partnerships: Signed 85 new agreements in 2025, including Florida Blue, UnitedHealthcare, and Premera Blue Cross, doubling the target. Expanded pipeline to $122 million with multi-condition deployments making up 80% of opportunities.
Distribution ecosystem: Access to over 160 million covered lives through partnerships with Solera Health, Amwell, and others. Expanded reach with Florida Blue and HCSC partnerships.
Revenue and cost efficiency: Sequential revenue growth in Q4 2025 to $5.2 million. Operating expenses reduced by 31% year-over-year, targeting cash flow breakeven by mid-2027.
Strategic opportunities: Engaged Perella Weinberg Partners to explore sale, merger, or strategic business combination. Process remains active.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legacy Client Nonrenewal: A single legacy client from pre-acquisition decided not to renew the contract, leading to a decline in annual revenue. This was described as a one-time situation but had a material impact on financial performance.
Revenue Dependency on New Contracts: The company's revenue growth is heavily reliant on onboarding and ramping new clients signed in 2025. Delays or challenges in these processes could impact revenue projections for 2026 and beyond.
Operational Efficiency Targets: The company aims to reduce operating loss by 30% in 2026 and achieve cash flow breakeven by mid-2027. Failure to meet these targets could strain financial resources.
Market Competition: The digital health market is consolidating, and competitors are also moving towards integrated multi-condition platforms. This could pressure DarioHealth to maintain its competitive edge.
Regulatory and Compliance Risks: The company operates in a highly regulated industry, and any changes in healthcare regulations or compliance requirements could adversely affect operations.
Dependence on Channel Partners: The company relies on channel partners like Solera Health and Amwell for distribution. Any disruptions or changes in these partnerships could impact scalability and revenue.
Economic Uncertainty: Broader economic uncertainties could affect employer and health plan budgets, potentially impacting demand for DarioHealth's solutions.
Pipeline Conversion Risks: The company has a large pipeline of commercial opportunities, but there is no guarantee that these will convert into revenue-generating contracts.
Technological Dependence: The company's competitive advantage is tied to its proprietary AI and data platform. Any technological failures or inability to keep up with advancements could weaken its market position.
Strategic Execution Risks: The company is exploring strategic opportunities, including a potential sale or merger. Uncertainty around these decisions could distract from operational focus.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expected timing and contribution of agreements signed in 2025 to revenue in 2026 and 2027: Agreements signed in 2025 are expected to contribute $12.9 million in contracted and late-stage ARR to revenue in 2026 and 2027.
Anticipated revenue growth trends and timing of acceleration during 2026: Revenue growth is expected to continue in the first quarter of 2026 and build throughout the year, with the strongest acceleration anticipated in the second half of 2026.
Expected onboarding, enrollment, and expansion of relationships: New clients signed in 2025 are still ramping enrollment and engagement, becoming growth drivers for 2026. Existing contracts provide a stable foundation with built-in member growth and expansion opportunities.
Pipeline of commercial opportunities: The pipeline has expanded to $122 million, providing near-term revenue visibility and a strong foundation for sustained growth.
Future operating efficiencies, margins, and expense reductions: The company expects to reduce its operating loss by 30% in 2026 and reach cash flow breakeven by mid-2027.
Strategic opportunities: The company is considering a range of strategic opportunities, including a sale, merger, strategic business combination, or continued execution of its stand-alone strategy.
Market trends and demand: Employers and health plans are moving towards integrated platforms addressing multiple conditions. Nearly 80% of the commercial pipeline involves multi-condition deployments, with demand for managing diabetes, hypertension, and mental health through a single platform.
Channel partnerships and payer ecosystems: Dario has access to over 160 million covered lives through its distribution ecosystem. New partnerships and expansions, such as with Florida Blue and Solera Health, are expected to contribute revenue starting in the second half of 2026 and into 2027.
Government-sponsored healthcare programs: Dario is engaged in discussions with state offices and channel partners to support the Federal Rural Health Transformation initiative, a $50 billion program rolling out over the next 5 years.
Employer and health plan pipeline: The employer pipeline includes 102 opportunities worth $54 million, while the health plan pipeline includes 81 opportunities worth $60 million. These opportunities are expected to drive growth in 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us a little sense on how the big contract starting in January is progressing and how should we think about revenue growth in 2026?
A:The company had 85 wins and a contracted ARR of $12.9 million, with some implementation already started. Growth is expected to accelerate in the second half of the year. While not providing guidance, the company feels comfortable with the current analyst consensus and aims to achieve or beat it.
Q:What is driving the delay in the target of breakeven?
A:80% of the delay is attributed to growth opportunities and 20% to optimizing OpEx. The company has reduced costs significantly over the last two years and plans to further reduce costs using AI. The top-line growth, with revenues in the range of $38 million to $42 million, is expected to drive cash flow positivity.
Q:What is the selection process for being a preferred partner with HCSC, and how does the company plan to take advantage of this opportunity?
A:The company is a preferred partner with Solera, making it 'in-network.' HCSC makes decisions with Solera, and self-insured employers decide on benefit designs. Fully insured books are controlled by HCSC. The company is working on execution and expects meaningful business from HCSC's large plans. Predictive modeling is used for self-insured capture rates, and the company is launching its largest fully insured client in January 2027.
Q:How should we think about operating expenses in 2026?
A:Operating expenses have been reduced significantly year-over-year and are expected to continue decreasing through 2026. The company projects a 30% reduction in non-GAAP operating loss in 2026 compared to 2025.
Q:What accounts for the big uptick in the commercial pipeline value from $69 million to $122 million?
A:The increase reflects a combined pipeline view for 2026 and 2027, whereas the previous quarter only included 2026.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARR opportunity
Blue Cross
Blue Shield
Cross Blue
DarioHealth End
Financial
Florida Blue
Layer
Today discussion
United States
access million
account population
addition channel
advantage
agreement
channel partner
compounding layer
contract extension
cycle
deployment
distribution ecosystem
ecosystem health
employer opportunity
example
expansion
expense
foundation
health care
multiplies
opportunity value
organization
payer ecosystem
plan opportunity
potential
record
year
DRIO Transcript
Sylogist Ltd. (SYZ:CA) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents mixed signals: while there are positive elements like improved recurring revenue gross margins and strategic partnerships, there are concerns about project service margins turning negative and soft SaaS ARR bookings due to timing issues. The Q&A reveals uncertainties about growth and margin progression, with management avoiding specific timelines. Despite a strong pipeline and transformational efforts, the lack of concrete guidance and ongoing transition phase temper overall optimism, suggesting a neutral stock price movement in the short term.
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
Positive3-19
Despite a revenue decline due to a legacy client nonrenewal, the company shows strong operational efficiency with reduced expenses and improved margins. Strategic partnerships with major health plans and a growing pipeline indicate future growth potential. The Q&A session highlighted confidence in meeting analyst expectations and achieving cash flow positivity. The company's proactive cost management and strategic partnerships are positive indicators, despite economic uncertainties and competitive pressures. Overall, these factors suggest a positive sentiment towards stock performance in the short term.
DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals several concerning factors: a 14.3% revenue decline, delayed cash flow breakeven, and client onboarding issues. Despite cost reductions and improved gross margins, the strategic shift to a SaaS model and competitive pressures pose risks. Q&A highlights management's unclear responses on financial impacts, further contributing to uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
DRIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
